We are joining forces with Canaccord Genuity

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market. This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you.

Since it was founded in 1988, Results has grown into a leading independent sector-focussed advisory firm, advising corporate, founder-owned and private equity clients on transactions in the healthcare and technology sectors. We’ve advised on over 60 transactions in our focus sectors in the last three years alone. The combination with Canaccord Genuity will enable us to enhance our global reach, expand our advisory capability and continue to deliver outstanding outcomes for our clients.

What We Do

We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your partner

M&A

When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business

Divestments

With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business

Licensing

We support clients with in-licensing and out-licensing of drugs, technologies and facilities. We understand the complexities that are unique to licensing deals

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses

Recent Deals

Jul 2022
has received investment from
Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
Has invested in
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Apr 2022
has received investment from
and EnBW New Ventures, with follow-on investment from ETF Partners
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF
Apr 2022
has been acquired by
Mar 2022
An AlbionVC-backed company
has received investment from
Morgan Stanley Expansion Capital and Keyhaven Capital Partners co-invest

Our People

Our M&A experts know the industry, we get to know you and your business – and we get results. The best possible results. We make new futures happen, and we make it enjoyable along the way. Because we know the right result is one you’ll feel great about.

Latest Insights